The Synaptic Vesicle Glycoprotein 2A pipeline drugs market research report outlays comprehensive information on the Synaptic Vesicle Glycoprotein 2A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Synaptic Vesicle Glycoprotein 2A pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Central Nervous System which include the indications Epilepsy, and Partial Seizure. It also reviews key players involved in Synaptic Vesicle Glycoprotein 2A targeted therapeutics development with respective active and dormant or discontinued products.
The Synaptic Vesicle Glycoprotein 2A pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, and Phase I stages are 1, 1, 1, and 2 respectively.
Synaptic Vesicle Glycoprotein 2A overview
Synaptic Vesicle Glycoprotein 2A is a protein that in humans is encoded by a gene SV2A. This protein plays a main role in neurotransmission and found in the membranes of synaptic vesicles, which are small membrane-bound compartments within nerve cells that store and release neurotransmitters. This protein regulates neurotransmitter release and target for antiepileptic medications.
For a complete picture of Synaptic Vesicle Glycoprotein 2A’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.